

Tetsuya Mitsudomi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2327726/publications.pdf>

Version: 2024-02-01

334
papers

42,323
citations

4658

85
h-index

2385

198
g-index

339
all docs

339
docs citations

339
times ranked

30507
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>EGFR</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. <i>Science</i> , 2007, 316, 1039-1043.	12.6	4,187
2	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2011, 6, 244-285.	1.1	4,127
3	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2010, 11, 121-128.	10.7	3,794
4	Reduced Expression of the <i>let-7</i> MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival. <i>Cancer Research</i> , 2004, 64, 3753-3756.	0.9	2,287
5	Mutations of the <i>Epidermal Growth Factor Receptor</i> Gene in Lung Cancer. <i>Cancer Research</i> , 2004, 64, 8919-8923.	0.9	1,168
6	EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors. <i>New England Journal of Medicine</i> , 2010, 363, 1734-1739.	27.0	1,124
7	Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non-Small-Cell Lung Cancer With Postoperative Recurrence. <i>Journal of Clinical Oncology</i> , 2005, 23, 2513-2520.	1.6	922
8	Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1973-1985.	27.0	871
9	Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. <i>Lancet</i> , The, 2017, 390, 29-39.	13.7	753
10	Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer and Acquired Resistance to Gefitinib. <i>Clinical Cancer Research</i> , 2006, 12, 5764-5769.	7.0	577
11	Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations. <i>Cancer Research</i> , 2008, 68, 9479-9487.	0.9	574
12	Reduced expression of <i>Dicer</i> associated with poor prognosis in lung cancer patients. <i>Cancer Science</i> , 2005, 96, 111-115.	3.9	573
13	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. <i>Cancer Science</i> , 2007, 98, 1817-1824.	3.9	554
14	Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. <i>Lancet</i> , The, 2022, 399, 1607-1617.	13.7	537
15	Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2016, 17, 1643-1652.	10.7	533
16	A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201). <i>Journal of Thoracic Oncology</i> , 2011, 6, 751-756.	1.1	505
17	Epidermal growth factor receptor in relation to tumor development: <i>EGFR</i> gene and cancer. <i>FEBS Journal</i> , 2010, 277, 301-308.	4.7	456
18	Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 822-835.	10.7	390

#	ARTICLE	IF	CITATIONS
19	TTF-1 Expression in Pulmonary Adenocarcinomas. American Journal of Surgical Pathology, 2002, 26, 767-773.	3.7	352
20	Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial. Journal of Thoracic and Cardiovascular Surgery, 2019, 158, 895-907.	0.8	347
21	Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Science, 2016, 107, 1179-1186.	3.9	305
22	Expression Profile—Defined Classification of Lung Adenocarcinoma Shows Close Relationship With Underlying Major Genetic Changes and Clinicopathologic Behaviors. Journal of Clinical Oncology, 2006, 24, 1679-1688.	1.6	296
23	Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nature Genetics, 2012, 44, 1330-1335.	21.4	286
24	Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers. Journal of Thoracic Oncology, 2009, 4, 5-11.	1.1	283
25	Impact of Specific Epidermal Growth Factor Receptor (<i>EGFR</i>) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in <i>EGFR</i>-Mutant Lung Cancer: A Meta-Analysis. Journal of Clinical Oncology, 2015, 33, 1958-1965.	1.6	280
26	Radiographically determined noninvasive adenocarcinoma of the lung: Survival outcomes of Japan Clinical Oncology Group 0201. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 24-30.	0.8	279
27	Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 1604-1611.e3.	0.8	245
28	Plasma ctDNA Analysis for Detection of the EGFR ÂT790M Mutation in Patients with Advanced Non—Small—Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1061-1070.	1.1	240
29	Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib. Journal of Thoracic Oncology, 2011, 6, 1152-1161.	1.1	233
30	EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma. American Journal of Surgical Pathology, 2005, 29, 633-639.	3.7	229
31	Predictors of Survival in Patients With Bone Metastasis of Lung Cancer. Clinical Orthopaedics and Related Research, 2008, 466, 729-736.	1.5	227
32	Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma. Journal of Thoracic Oncology, 2009, 4, 22-29.	1.1	222
33	Heterogeneous Distribution of <i>EGFR</i> Mutations Is Extremely Rare in Lung Adenocarcinoma. Journal of Clinical Oncology, 2011, 29, 2972-2977.	1.6	218
34	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 2020, 15, 709-740.	1.1	205
35	Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. International Journal of Cancer, 2004, 112, 26-32.	5.1	203
36	Lineage-Specific Dependency of Lung Adenocarcinomas on the Lung Development Regulator TTF-1. Cancer Research, 2007, 67, 6007-6011.	0.9	200

#	ARTICLE	IF	CITATIONS
37	Reciprocal and Complementary Role of <i>MET</i> Amplification and <i>EGFR</i> T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 5489-5498.	7.0	200
38	Mutations of the p53 Gene as a Predictor of Poor Prognosis in Patients With Non-Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 1993, 85, 2018-2023.	6.3	196
39	Hepatocyte Growth Factor Expression in <i>EGFR</i> Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort. <i>Journal of Thoracic Oncology</i> , 2011, 6, 2011-2017.	1.1	196
40	Gefitinib or Erlotinib vs Chemotherapy for <i>EGFR</i> Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	196
41	Biological and clinical implications of <i>EGFR</i> mutations in lung cancer. <i>International Journal of Clinical Oncology</i> , 2006, 11, 190-198.	2.2	194
42	Relapse-Related Molecular Signature in Lung Adenocarcinomas Identifies Patients With Dismal Prognosis. <i>Journal of Clinical Oncology</i> , 2009, 27, 2793-2799.	1.6	194
43	Biological and clinical significance of <i>KRAS</i> mutations in lung cancer: an oncogenic driver that contrasts with <i>EGFR</i> mutation. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 49-60.	5.9	191
44	Phase II Trial of Preoperative Chemoradiotherapy Followed by Surgical Resection in Patients With Superior Sulcus Non-Small-Cell Lung Cancers: Report of Japan Clinical Oncology Group Trial 9806. <i>Journal of Clinical Oncology</i> , 2008, 26, 644-649.	1.6	182
45	Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non-Small Cell Lung Cancer with <i>EGFR</i> Mutations. <i>Clinical Cancer Research</i> , 2009, 15, 4493-4498.	7.0	182
46	A Rapid, Sensitive Assay to Detect <i>EGFR</i> Mutation in Small Biopsy Specimens from Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 335-341.	2.8	178
47	The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of <i>EGFR</i> Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. <i>Journal of Thoracic Oncology</i> , 2016, 11, 946-963.	1.1	173
48	<i>EGFR</i> T790M Mutation: A Double Role in Lung Cancer Cell Survival?. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1-4.	1.1	167
49	<i>EGFR</i> Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. <i>Clinical Cancer Research</i> , 2015, 21, 5305-5313.	7.0	164
50	Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 1372-1375.	0.7	161
51	Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6092-6096.	7.0	159
52	A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, 289-301.e2.	0.8	159
53	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv279.	6.3	152
54	Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1415-1419.	1.1	151

#	ARTICLE	IF	CITATIONS
55	Prognostic Model of Pulmonary Adenocarcinoma by Expression Profiling of Eight Genes As Determined by Quantitative Real-Time Reverse Transcriptase Polymerase Chain Reaction. <i>Journal of Clinical Oncology</i> , 2004, 22, 811-819.	1.6	148
56	Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. <i>Oncogene</i> , 2004, 23, 5360-5370.	5.9	140
57	Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). <i>Lung Cancer</i> , 2016, 98, 69-75.	2.0	136
58	Epidermal Growth Factor Receptor Gene Amplification Is Acquired in Association with Tumor Progression of EGFR-Mutated Lung Cancer. <i>Cancer Research</i> , 2008, 68, 2106-2111.	0.9	134
59	Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 22-28.	1.1	134
60	Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. <i>Lung Cancer</i> , 2011, 74, 139-144.	2.0	132
61	Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation—diversity, ductility, and destiny. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 807-814.	5.9	132
62	Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. <i>Carcinogenesis</i> , 2004, 25, 1395-1401.	2.8	126
63	Expression of cancer/testis (CT) antigens in lung cancer. <i>Lung Cancer</i> , 2003, 42, 23-33.	2.0	123
64	Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. <i>Oncogene</i> , 2002, 21, 2328-2333.	5.9	119
65	EGFR Mutation and Response of Lung Cancer to Gefitinib. <i>New England Journal of Medicine</i> , 2005, 352, 2136-2136.	27.0	118
66	KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1321-1332.	1.1	118
67	Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. <i>Cancer</i> , 2019, 125, 892-901.	4.1	117
68	Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012. <i>Journal of Thoracic Oncology</i> , 2013, 8, 373-384.	1.1	113
69	A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). <i>Cancer</i> , 2012, 118, 6126-6135.	4.1	111
70	Completely resected stage IIIA non-small cell lung cancer: The significance of primary tumor location and N2 station. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2001, 122, 803-808.	0.8	109
71	Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 3349-3355.	7.0	108
72	Molecular Diagnosis of Activating EGFR Mutations in Non-Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis. <i>Clinical Cancer Research</i> , 2010, 16, 3163-3170.	7.0	108

#	ARTICLE	IF	CITATIONS
73	Impact of EGFR mutation analysis in non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 63, 315-321.	2.0	107
74	Effect of selective lymph node dissection based on patterns of lobe-specific lymph node metastases on patient outcome in patients with resectable non-small cell lung cancer: A large-scale retrospective cohort study applying a propensity score. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2010, 139, 1001-1006.	0.8	107
75	Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1640-1644.	1.1	107
76	Surgical treatment of lung cancer in the octogenarian. <i>Annals of Thoracic Surgery</i> , 1994, 57, 188-192.	1.3	105
77	Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1753-1765.	1.1	105
78	Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1997, 114, 535-543.	0.8	103
79	Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. <i>Lung Cancer</i> , 2012, 77, 319-325.	2.0	102
80	Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 195-199.	2.0	100
81	Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2006, 1, 120-125.	1.1	94
82	A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711AL (PEOPLE Study). <i>Respiratory Research</i> , 2016, 17, 90.	3.6	93
83	How Long Should Small Lung Lesions of Ground-Glass Opacity be Followed?. <i>Journal of Thoracic Oncology</i> , 2013, 8, 309-314.	1.1	91
84	Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. <i>Annals of Thoracic Surgery</i> , 1997, 64, 363-367.	1.3	90
85	CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. <i>Journal of Pathology</i> , 2004, 203, 645-652.	4.5	88
86	The association between baseline clinical and radiological characteristics and growth of pulmonary nodules with ground-glass opacity. <i>Lung Cancer</i> , 2014, 83, 61-66.	2.0	87
87	Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. <i>Cancer Science</i> , 2007, 98, 96-101.	3.9	86
88	Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including <i>JUN</i> amplification on 1p32. <i>Cancer Science</i> , 2007, 98, 438-446.	3.9	86
89	Surgery for NSCLC in the era of personalized medicine. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 235-244.	27.6	85
90	CRIP1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. <i>Journal of Clinical Investigation</i> , 2014, 124, 3003-3015.	8.2	84

#	ARTICLE	IF	CITATIONS
91	Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?. Translational Lung Cancer Research, 2013, 2, 354-63.	2.8	84
92	Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer, 2001, 34, 29-36.	2.0	82
93	The Impact of Sex and Smoking Status on the Mutational Spectrum of Epidermal Growth Factor Receptor Gene in Non-small Cell Lung Cancer. Clinical Cancer Research, 2007, 13, 5763-5768.	7.0	81
94	Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer. Molecular Cancer Therapeutics, 2012, 11, 2149-2157.	4.1	81
95	EGFR mutations in patients with brain metastases from lung cancer: Association with the efficacy of gefitinib. Neuro-Oncology, 2006, 8, 137-144.	1.2	80
96	Lung cancer in never smokers: Change of a mindset in the molecular era. Lung Cancer, 2011, 72, 9-15.	2.0	78
97	Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?. Cancer Science, 2016, 107, 1134-1140.	3.9	78
98	Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2020, 38, 2187-2196.	1.6	78
99	Inflammatory pseudotumor of the lung in adults: Radiographic and clinicopathological analysis. Annals of Thoracic Surgery, 1989, 48, 90-95.	1.3	75
100	HNF4 α as a Marker for Invasive Mucinous Adenocarcinoma of the Lung. American Journal of Surgical Pathology, 2013, 37, 211-218.	3.7	74
101	A 25-Signal Proteomic Signature and Outcome for Patients With Resected Non-Small-Cell Lung Cancer. Journal of the National Cancer Institute, 2007, 99, 858-867.	6.3	73
102	Advances in Target Therapy for Lung Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 101-106.	1.3	73
103	Epidermal growth factor receptor mutations in lung cancers. Pathology International, 2007, 57, 233-244.	1.3	72
104	Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. International Journal of Cancer, 2015, 137, 311-319.	5.1	72
105	Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2007, 2, 22-28.	1.1	71
106	Increased Prevalence of EGFR-Mutant Lung Cancer in Women and in East Asian Populations: Analysis of Estrogen-Related Polymorphisms. Clinical Cancer Research, 2008, 14, 4079-4084.	7.0	71
107	A Screening Method for the ALK Fusion Gene in NSCLC. Frontiers in Oncology, 2012, 2, 24.	2.8	71
108	Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer. Scientific Reports, 2015, 5, 14447.	3.3	71

#	ARTICLE	IF	CITATIONS
109	Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).. Journal of Clinical Oncology, 2012, 30, 7521-7521.	1.6	71
110	A Limited Association of OGG1 Ser326Cys Polymorphism for Adenocarcinoma of the Lung.. Journal of Epidemiology, 2002, 12, 258-265.	2.4	69
111	Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. Journal of Thoracic Oncology, 2007, 2, 22-8.	1.1	69
112	PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients. Journal of Thoracic Oncology, 2006, 1, 629-634.	1.1	68
113	Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a caseâ€“control study. Carcinogenesis, 2007, 28, 1718-1725.	2.8	68
114	Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese. International Archives of Occupational and Environmental Health, 1995, 67, 253-256.	2.3	67
115	Mutations of epidermal growth factor receptor andK-rasgenes in adenosquamous carcinoma of the lung. International Journal of Cancer, 2006, 118, 1588-1590.	5.1	66
116	Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer Cases. Annals of Thoracic Surgery, 2021, 111, 269-276.	1.3	66
117	RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. International Journal of Cancer, 2003, 106, 45-51.	5.1	65
118	Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer. Molecular Cancer Therapeutics, 2017, 16, 357-364.	4.1	65
119	The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 (â€“Iressaâ€“™) is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer, 2003, 42, 35-41.	2.0	64
120	Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations. Translational Lung Cancer Research, 2014, 3, 205-11.	2.8	64
121	Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. Lung Cancer, 2018, 121, 37-40.	2.0	62
122	Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-III Nonâ€“Small-Cell Lung Cancer With <i>EGFR</i> Mutation (IMPACT). Journal of Clinical Oncology, 2022, 40, 231-241.	1.6	61
123	Postoperative complications after pneumonectomy for treatment of lung cancer: Multivariate analysis. Journal of Surgical Oncology, 1996, 61, 218-222.	1.7	60
124	Molecular oncology of lung cancer. General Thoracic and Cardiovascular Surgery, 2011, 59, 527-537.	0.9	60
125	Personalized therapy on the horizon for squamous cell carcinoma of the lung. Lung Cancer, 2013, 80, 249-255.	2.0	60
126	Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. Lung Cancer, 2018, 126, 72-79.	2.0	59

#	ARTICLE	IF	CITATIONS
127	Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2006, 1, 120-125.	1.1	58
128	A clinicopathological study of gastric cancer with special reference to age of the patients: An analysis of 1,630 cases. World Journal of Surgery, 1989, 13, 225-230.	1.6	56
129	Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. Lung Cancer, 2012, 76, 292-299.	2.0	56
130	Mutations of the p53 tumor suppressor gene as clonal marker for multiple primary lung cancers. Journal of Thoracic and Cardiovascular Surgery, 1997, 114, 354-360.	0.8	55
131	PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. Journal of Thoracic Oncology, 2006, 1, 629-34.	1.1	53
132	Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation. Oncogene, 2004, 23, 4041-4049.	5.9	52
133	EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR and KRAS Mutations in a Japanese Cohort. Journal of Thoracic Oncology, 2009, 4, 318-325.	1.1	52
134	Salvage surgery for advanced non-small cell lung cancer after response to gefitinib. Journal of Thoracic and Cardiovascular Surgery, 2010, 140, e69-e71.	0.8	52
135	Longer survival after resection of non-small cell lung cancer in Japanese women. Annals of Thoracic Surgery, 1989, 48, 639-642.	1.3	51
136	LKB1 gene mutations in Japanese lung cancer patients. Cancer Science, 2007, 98, 1747-1751.	3.9	51
137	hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological type. Journal of Human Genetics, 2009, 54, 739-745.	2.3	50
138	Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. Human Molecular Genetics, 2016, 26, ddw414.	2.9	50
139	Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. Human Molecular Genetics, 2016, 25, 620-629.	2.9	50
140	The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor. International Journal of Cancer, 2014, 135, 1002-1006.	5.1	49
141	Significant up-regulation of a novel gene, CLCP1, in a highly metastatic lung cancer subline as well as in lung cancers in vivo. Oncogene, 2002, 21, 2822-2828.	5.9	48
142	Efficiency of serum copper/zinc ratio for differential diagnosis of patients with and without lung cancer. Biological Trace Element Research, 1994, 42, 115-127.	3.5	47
143	A prematurely terminated phase III trial of intraoperative intrapleural hypotonic cisplatin treatment in patients with resected non-small cell lung cancer with positive pleural lavage cytology: The incidence of carcinomatous pleuritis after surgical intervention. Journal of Thoracic and Cardiovascular Surgery, 2002, 123, 695-699.	0.8	47
144	Persistent Increase in Chromosome Instability in Lung Cancer. American Journal of Pathology, 2001, 159, 1345-1352.	3.8	45

#	ARTICLE	IF	CITATIONS
145	Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights. Translational Lung Cancer Research, 2018, 7, 487-497.	2.8	45
146	Surgical Outcomes of Lung Cancer in Patients with Combined Pulmonary Fibrosis and Emphysema. Annals of Surgical Oncology, 2015, 22, 1371-1379.	1.5	44
147	p53 Immunostaining Positivity Is Associated With Reduced Survival and Is Imperfectly Correlated With Gene Mutations in Resected Non-small Cell Lung Cancer. Chest, 1994, 106, 377S-381S.	0.8	43
148	Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach. Oncogene, 2007, 26, 4600-4608.	5.9	43
149	Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer, 2013, 81, 97-101.	2.0	42
150	Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. Archives of Toxicology, 2015, 89, 1227-1240.	4.2	42
151	CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. Molecular Cancer Therapeutics, 2018, 17, 2257-2265.	4.1	41
152	Brain metastases in oncogene-driven non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, S298-S307.	2.8	41
153	Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. Lung Cancer, 2018, 126, 149-155.	2.0	40
154	Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells. Lung Cancer, 2017, 104, 85-90.	2.0	39
155	EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib. Journal of Thoracic Oncology, 2018, 13, 727-731.	1.1	39
156	Serum Level and Tissue Expression of c-erbB-2 Protein in Lung Adenocarcinoma. Chest, 1995, 108, 157-162.	0.8	38
157	Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. General Thoracic and Cardiovascular Surgery, 2008, 56, 97-103.	0.9	38
158	Impact of smoking on lung cancer risk is stronger in those with the homozygous aldehyde dehydrogenase 2 null allele in a Japanese population. Carcinogenesis, 2010, 31, 660-665.	2.8	38
159	Interstitial Lung Disease Associated with Gefitinib in Japanese Patients with EGFR-mutated Non-small-cell Lung Cancer: Combined Analysis of Two Phase III Trials (NEJ 002 and WJTOG 3405). Japanese Journal of Clinical Oncology, 2013, 43, 664-668.	1.3	38
160	Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. Lung Cancer, 2016, 91, 36-40.	2.0	38
161	Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. Cancer Science, 2008, 99, 303-308.	3.9	37
162	Association between a Genome-Wide Association Study-Identified Locus and the Risk of Lung Cancer in Japanese Population. Journal of Thoracic Oncology, 2012, 7, 790-798.	1.1	37

#	ARTICLE	IF	CITATIONS
163	Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies. <i>Journal of Thoracic Oncology</i> , 2013, 8, e75-e78.	1.1	37
164	Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib. <i>ESMO Open</i> , 2016, 1, e000063.	4.5	37
165	MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. <i>Annals of Thoracic Surgery</i> , 1999, 67, 810-814.	1.3	36
166	Expression of human telomerase subunit genes in primary lung cancer and its clinical significance. <i>Annals of Thoracic Surgery</i> , 2000, 70, 401-405.	1.3	36
167	Impact of age on epidermal growth factor receptor mutation in lung cancer. <i>Lung Cancer</i> , 2012, 78, 207-211.	2.0	35
168	Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification. <i>International Journal of Cancer</i> , 2016, 138, 1024-1032.	5.1	35
169	Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?. <i>Lancet Oncology</i> , The, 2011, 12, 710-711.	10.7	34
170	Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1078-1085.	1.1	34
171	Successes and Limitations of Targeted Cancer Therapy in Lung Cancer. <i>Progress in Tumor Research</i> , 2014, 41, 62-77.	0.1	34
172	The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations. <i>Therapeutic Advances in Medical Oncology</i> , 2010, 2, 301-307.	3.2	33
173	Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. <i>Lung Cancer</i> , 2022, 170, 41-51.	2.0	33
174	Relationship of Deregulated Signaling Converging onto mTOR with Prognosis and Classification of Lung Adenocarcinoma Shown by Two Independent In silico Analyses. <i>Cancer Research</i> , 2009, 69, 4027-4035.	0.9	32
175	Paravertebral block via the surgical field versus epidural block for patients undergoing thoracotomy: a randomized clinical trial. <i>Surgery Today</i> , 2013, 43, 963-969.	1.5	32
176	MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. <i>Lung Cancer</i> , 2015, 90, 590-597.	2.0	32
177	Outcomes After Hepatic and Pulmonary Metastasectomies Compared With Pulmonary Metastasectomy Alone in Patients With Colorectal Cancer Metastasis to Liver and Lungs. <i>World Journal of Surgery</i> , 2013, 37, 1315-1321.	1.6	31
178	FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. <i>Cancer Science</i> , 2016, 107, 1667-1676.	3.9	31
179	Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor in lung cancer. <i>Cancer Science</i> , 2016, 107, 461-468.	3.9	31
180	Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. <i>BMC Cancer</i> , 2017, 17, 281.	2.6	31

#	ARTICLE	IF	CITATIONS
181	Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. Lung Cancer, 1998, 20, 117-125.	2.0	30
182	Decreased expression of 14-3-3 β in neuroendocrine tumors is independent of origin and malignant potential. Oncogene, 2002, 21, 8310-8319.	5.9	30
183	Clinicopathological features of small-sized non-small cell lung cancer with mediastinal lymph node metastasis. Lung Cancer, 2009, 66, 309-313.	2.0	30
184	Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for Stage III non-small-cell lung cancer. Interactive Cardiovascular and Thoracic Surgery, 2016, 23, 895-901.	1.1	30
185	PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients. Journal of Thoracic Oncology, 2006, 1, 629-634.	1.1	28
186	Soy consumption reduces the risk of non-small cell lung cancers with epidermal growth factor receptor mutations among Japanese. Cancer Science, 2008, 99, 1202-1208.	3.9	28
187	Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. Lung Cancer, 2021, 153, 108-116.	2.0	28
188	Fluid Drainage and Air Evacuation Characteristics of Blake and Conventional Drains Used After Pulmonary Resection. Annals of Thoracic Surgery, 2009, 87, 1539-1545.	1.3	27
189	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer, 2017, 109, 1-8.	2.0	27
190	Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. Expert Review of Anticancer Therapy, 2017, 17, 779-786.	2.4	27
191	Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. Expert Opinion on Emerging Drugs, 2020, 25, 229-249.	2.4	27
192	Large Cell Carcinoma of the Lung: Prognostic Implications of Histopathologic and Immunohistochemical Subtyping. American Journal of Clinical Pathology, 1990, 93, 176-182.	0.7	26
193	Kinetic analysis of recurrence and survival after potentially curative resection of nonsmall cell lung cancer. , 1996, 63, 159-165.		26
194	Interferon- γ differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes. International Journal of Cancer, 2004, 110, 403-412.	5.1	26
195	Patterns of recurrence and outcome in patients with surgically resected small cell lung cancer. International Journal of Clinical Oncology, 2012, 17, 218-224.	2.2	26
196	Invasive human fibrosarcoma DNA mediated induction of a 92 kDa gelatinase/type IV collagenase leads to an invasive phenotype. Biochemical and Biophysical Research Communications, 1991, 181, 1539-1547.	2.1	25
197	Frequent loss of the short arm of chromosome 9 in resected non-small-cell lung cancers from Japanese patients and its association with squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 1995, 121, 291-296.	2.5	25
198	Topographical Distributions of Allelic Loss in Individual Non-Small-Cell Lung Cancers. American Journal of Pathology, 2000, 157, 985-993.	3.8	25

#	ARTICLE	IF	CITATIONS
199	Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage IIa–IIIA Non–Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5245-5252.	7.0	25
200	The novel one-step nucleic acid amplification (OSNA) assay for the diagnosis of lymph node metastasis in patients with non-small cell lung cancer (NSCLC): Results of a multicenter prospective study. <i>Lung Cancer</i> , 2016, 97, 1-7.	2.0	25
201	Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 35-50.	2.7	25
202	MEK inhibitors against MET-amplified non-small cell lung cancer. <i>International Journal of Oncology</i> , 2016, 49, 2236-2244.	3.3	24
203	Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. <i>Journal of Thoracic Oncology</i> , 2017, 12, 27-35.	1.1	24
204	Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non–small cell lung cancers. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2008, 136, 1343-1348.	0.8	23
205	Novel Metastasis-Related Gene CIM Functions in the Regulation of Multiple Cellular Stress–Response Pathways. <i>Cancer Research</i> , 2010, 70, 9949-9958.	0.9	23
206	Lung cancers unrelated to smoking: characterized by single oncogene addiction?. <i>International Journal of Clinical Oncology</i> , 2011, 16, 294-305.	2.2	23
207	Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2618-2628.	2.8	23
208	Subcategorization of Lung Cancer Based on Tumor Size and Degree of Visceral Pleural Invasion—The main results from this paper were previously published in the Japanese Journal of Lung Cancer, in Japanese [16].. <i>Annals of Thoracic Surgery</i> , 2008, 86, 1084-1090.	1.3	22
209	Preoperative evaluation of the depth of chest wall invasion and the extent of combined resections in lung cancer patients. <i>Lung Cancer</i> , 2009, 64, 41-44.	2.0	22
210	Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1496-1507.	1.1	22
211	Osimertinib for Japanese patients with T790M–positive advanced non–small–cell lung cancer: A pooled subgroup analysis. <i>Cancer Science</i> , 2019, 110, 2884-2893.	3.9	22
212	Pulmonary metastasectomy for gastric cancer: a 13-year single-institution experience. <i>Surgery Today</i> , 2013, 43, 1382-1389.	1.5	20
213	Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1015-1020.	1.1	20
214	Throwing new light on lung cancer pathogenesis: Updates on three recent topics. <i>Cancer Science</i> , 2005, 96, 63-68.	3.9	19
215	Small peripheral lung adenocarcinoma: Clinicopathological features and surgical treatment. <i>Surgery Today</i> , 2010, 40, 191-198.	1.5	19
216	Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	17.0	19

#	ARTICLE	IF	CITATIONS
217	Neuroendocrine tumor metastasis to the thyroid gland. International Journal of Clinical Oncology, 2007, 12, 63-67.	2.2	18
218	Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 4035.	3.7	18
219	Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. Lung Cancer, 2009, 63, 241-246.	2.0	17
220	Lung Cancer Working Group Report. Japanese Journal of Clinical Oncology, 2010, 40, i7-i12.	1.3	17
221	The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 792-800.	1.1	17
222	Abortive transformation of temperature-sensitive mutants of rat 3Y1 cells by simian virus 40: Effect of cellular arrest states on entry into S phase and cellular proliferation. Journal of Cellular Physiology, 1985, 123, 353-360.	4.1	16
223	Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. General Thoracic and Cardiovascular Surgery, 2001, 49, 545-551.	0.4	16
224	Factors involved in lymph node metastasis in clinical stage I non-small cell lung cancer—From studies of 604 surgical cases. Lung Cancer, 2007, 57, 311-316.	2.0	16
225	Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures. Annals of Thoracic Surgery, 2008, 86, 1076-1083.	1.3	16
226	Validation of a Nomogram for Predicting Overall Survival After Resection of Pulmonary Metastases from Colorectal Cancer at a Single Center. World Journal of Surgery, 2010, 34, 2973-2978.	1.6	16
227	Recent evidence, advances, and current practices in surgical treatment of lung cancer. Respiratory Investigation, 2014, 52, 322-329.	1.8	16
228	Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer. Lung Cancer, 2017, 112, 57-61.	2.0	16
229	Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations. Cells, 2021, 10, 1590.	4.1	16
230	Analysis of β -tubulin gene alteration in human lung cancer cell lines. Cancer Letters, 2003, 201, 211-216.	7.2	15
231	Identification of MGB1 as a Marker in the Differential Diagnosis of Lung Tumors in Patients with a History of Breast Cancer by Analysis of Publicly Available SAGE Data. Journal of Molecular Diagnostics, 2004, 6, 90-95.	2.8	15
232	Controversy about Small Peripheral Lung Adenocarcinomas: How Should We Manage Them?. Journal of Thoracic Oncology, 2007, 2, 546-552.	1.1	15
233	Usefulness of cumulative smoking dose for identifying the <i>EGFR</i> mutation and patients with non-small cell lung cancer for gefitinib treatment. Cancer Science, 2009, 100, 1931-1934.	3.9	15
234	Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. Journal of Cancer Research and Clinical Oncology, 2010, 136, 527-535.	2.5	15

#	ARTICLE	IF	CITATIONS
235	Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression. PLoS ONE, 2016, 11, e0154186.	2.5	15
236	Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women. Genomics, 2020, 112, 1223-1232.	2.9	15
237	Activity of <i>tarloxotinib</i> in cells with <i>EGFR</i> exon20 insertion mutations and mechanisms of acquired resistance. Thoracic Cancer, 2021, 12, 1511-1516.	1.9	15
238	Stepwise examination for differential diagnosis of primary lung cancer and breast cancer relapse presenting as a solitary pulmonary nodule in patients after mastectomy. Journal of Surgical Oncology, 2008, 98, 510-514.	1.7	14
239	Rapid Detection of the Epidermal Growth Factor Receptor Mutation in Non-Small-Cell Lung Cancer for Analysis of Acquired Resistance Using Molecular Beacons. Journal of Molecular Diagnostics, 2010, 12, 644-652.	2.8	14
240	Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of <i>DDR2</i> . Clinical Cancer Research, 2016, 22, 3663-3671.	7.0	14
241	Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. Clinical Drug Investigation, 2018, 38, 319-331.	2.2	14
242	Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L). Clinical Lung Cancer, 2021, 22, 596-600.	2.6	14
243	Phenotypic characterization of lymphokine-activated killer cells from human lymph node lymphocytes. Cellular Immunology, 1989, 122, 578-584.	3.0	13
244	CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation. Lung Cancer, 2014, 85, 147-151.	2.0	13
245	Lack of Association between the BIM Deletion Polymorphism and the Risk of Lung Cancer with and without EGFR Mutations. Journal of Thoracic Oncology, 2015, 10, 59-66.	1.1	13
246	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. Clinical Lung Cancer, 2017, 18, 719-723.	2.6	13
247	Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. BioMed Research International, 2017, 2017, 1-7.	1.9	13
248	Adjuvant therapy of operable nonsmall cell lung cancer: an update. Current Opinion in Oncology, 2021, 33, 47-54.	2.4	13
249	Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. PLoS ONE, 2017, 12, e0172209.	2.5	13
250	Successful management of tracheo-innominate artery fistula using interposition of a thymus pedicle flap. Journal of Laryngology and Otology, 1995, 109, 161-162.	0.8	12
251	Knockdown of the Epidermal Growth Factor Receptor Gene to Investigate Its Therapeutic Potential for the Treatment of Non-Small-Cell Lung Cancers. Clinical Lung Cancer, 2012, 13, 488-493.	2.6	12
252	Significance of the serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small-cell lung cancer. European Journal of Cardio-thoracic Surgery, 2014, 45, 687-692.	1.4	12

#	ARTICLE	IF	CITATIONS
253	RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer. <i>Lung Cancer</i> , 2014, 83, 23-29.	2.0	12
254	Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib. <i>PLoS ONE</i> , 2015, 10, e0123901.	2.5	12
255	Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naïve Isogenic Lung Cancer Lesions with EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1711-1717.	1.1	12
256	DNA polymerase- β as a putative early relapse marker in non-small cell lung cancer. An immunohistochemical study. <i>Cancer</i> , 1991, 68, 925-929.	4.1	11
257	CT and MRI manifestations of primary pulmonary plasmacytoma. <i>Clinical Imaging</i> , 1995, 19, 17-19.	1.5	11
258	Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: A retrospective case-matching cohort study. <i>Surgical Oncology</i> , 2010, 19, e144-e149.	1.6	11
259	Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas. <i>Biomolecules</i> , 2019, 9, 456.	4.0	11
260	Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making?. <i>Journal of Thoracic Disease</i> , 2020, 12, 1770-1775.	1.4	11
261	Utility of the Ba/F3 cell system for exploring onâ€target mechanisms of resistance to targeted therapies for lung cancer. <i>Cancer Science</i> , 2022, 113, 815-827.	3.9	11
262	Aspergilloma Within Cavitating Pulmonary Carcinoma: Case Report. <i>Scandinavian Journal of Thoracic and Cardiovascular Surgery</i> , 1993, 27, 57-60.	0.2	10
263	Risk assessment of perioperative mortality after pulmonary resection in patients with primary lung cancer: the 30- or 90-day mortality. <i>General Thoracic and Cardiovascular Surgery</i> , 2014, 62, 308-313.	0.9	10
264	Prognosis and segmentâ€specific nodal spread of primary lung cancer in the right lower lobe. <i>Thoracic Cancer</i> , 2015, 6, 672-677.	1.9	10
265	Analysis of ERBB4 Mutations and Expression in Japanese Patients with Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1859-1861.	1.1	9
266	Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically Resected Lung Adenocarcinoma. <i>BioMed Research International</i> , 2014, 2014, 1-6.	1.9	9
267	Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancersâ€Applications and Limitations. <i>Cells</i> , 2021, 10, 354.	4.1	9
268	Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer. <i>Lung Cancer</i> , 2021, 154, 84-91.	2.0	9
269	Solitary pulmonary metastasis from lung cancer harboring EML4â€ALK after a 15-year disease-free interval. <i>Lung Cancer</i> , 2013, 80, 99-101.	2.0	8
270	Prognostic impact of pleural lavage cytology in patients with primary lung cancer. <i>Lung Cancer</i> , 2016, 102, 60-64.	2.0	8

#	ARTICLE	IF	CITATIONS
271	Characteristics of non-small cell lung cancer 3 cm or less in diameter. Journal of Surgical Oncology, 1995, 59, 251-254.	1.7	7
272	Activity and mechanism of acquired resistance to tarloxotinib in HER2 mutant lung cancer: an in vitro study. Translational Lung Cancer Research, 2021, 10, 3659-3670.	2.8	7
273	Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer harboring activating EGFR mutation (WJOG6410L).. Journal of Clinical Oncology, 2012, 30, TPS7110-TPS7110.	1.6	7
274	Genetic analysis of the catalytic domain of the GAP gene in human lung cancer cell lines. Human Genetics, 1994, 93, 27-31.	3.8	6
275	Dacomitinib: another option for EGFR-mutant lung cancer?. Lancet Oncology, The, 2014, 15, 1408-1409.	10.7	6
276	Racial Differences in Lung Cancer Genetics. Journal of Thoracic Oncology, 2015, 10, 230-231.	1.1	6
277	Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?. Translational Lung Cancer Research, 2016, 5, 446-449.	2.8	6
278	Heterogeneity in Tumors and Resistance to EGFR TKI Therapy Letter. Cancer Research, 2016, 76, 3109-3110.	0.9	6
279	Clinical outcome of node-negative oligometastatic non-small cell lung cancer. Thoracic Cancer, 2016, 7, 670-675.	1.9	6
280	Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR-mutant Ba/F3 cells. Oncology Reports, 2018, 41, 1059-1066.	2.6	6
281	Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. Lung Cancer, 2020, 148, 100-104.	2.0	6
282	Abstract 2101A: CNX-2006, a novel irreversible epidermal growth factor receptor (EGFR) inhibitor, selectively inhibits EGFR T790M and fails to induce T790M-mediated resistance <i>in vitro</i>.. Cancer Research, 2013, 73, 2101A-2101A.	0.9	6
283	Giant hamartoma of the lung with a high production of carbohydrate antigen 19-9. Annals of Thoracic Surgery, 1993, 55, 511-513.	1.3	5
284	The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer. Personalized Medicine, 2004, 1, 27-34.	1.5	5
285	The Effect of Gefitinib on B-RAF Mutant Non-small Cell Lung Cancer and Transfectants. Journal of Thoracic Oncology, 2007, 2, 321-324.	1.1	5
286	Lymph node metastasis of an esophageal cancer behind the thoracic descending aorta. Esophagus, 2010, 7, 111-114.	1.9	5
287	Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases. Clinical Lung Cancer, 2021, 22, e141-e145.	2.6	5
288	A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group) Tj ETQq0 0 0 rgBT2 Overlook 10 Tf 50		

#	ARTICLE	IF	CITATIONS
289	EGFR Gene Mutations: Is it Prognostic or Predictive in Surgically Resected Lung Cancer?. Journal of Thoracic Oncology, 2012, 7, 1739-1741.	1.1	4
290	Progression after spontaneous regression in lung large cell neuroendocrine carcinoma: Report of a curative resection. Thoracic Cancer, 2015, 6, 655-658.	1.9	4
291	Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer Research and Treatment, 2020, 52, 284-291.	3.0	4
292	Genetic and Prognostic Differences of Non-small Cell Lung Cancer between Elderly Patients and Younger Counterparts. , 2012, 3, 438-43.		4
293	Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. Lung Cancer, 1994, 10, S73-S81.	2.0	3
294	Comparison of methods for placing and managing a silastic drain after pulmonary resection. Interactive Cardiovascular and Thoracic Surgery, 2009, 9, 645-648.	1.1	3
295	Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond. Lung Cancer: Targets and Therapy, 2013, 4, 43.	2.7	3
296	Life-threatening complications after pulmonary resection for lung cancer in patients on chronic hemodialysis. Surgery Today, 2019, 49, 513-520.	1.5	3
297	BRAF Fusion “ Another Mechanism of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Journal of Thoracic Oncology, 2019, 14, 764-765.	1.1	3
298	Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor. JTO Clinical and Research Reports, 2021, 2, 100134.	1.1	3
299	Frequent EGFR mutations and better prognosis in positron emission tomography-negative, solid-type lung cancer. Clinical Lung Cancer, 2021, , .	2.6	3
300	Papillary Carcinoma in A Huge Intrathoracic Goiter with Tracheal Stenosis and Invasion. Scandinavian Journal of Thoracic and Cardiovascular Surgery, 1993, 27, 165-168.	0.2	2
301	M03-01: Molecular predictors of EGFR-TKIs. Journal of Thoracic Oncology, 2007, 2, S156.	1.1	2
302	Unintentional Weakness of Cancers: The MEK“ERK Pathway as a Double-Edged Sword. Molecular Cancer Research, 2013, 11, 1125-1128.	3.4	2
303	Integrin“linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma. Oncology Letters, 2021, 21, 320.	1.8	2
304	Postoperative complications after pneumonectomy for treatment of lung cancer: Multivariate analysis. Journal of Surgical Oncology, 1996, 61, 218-222.	1.7	2
305	EGFR mutations in non-small-cell lung cancer “ Authors' reply. Lancet Oncology, The, 2010, 11, 413.	10.7	1
306	Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis. Surgical Case Reports, 2019, 5, 105.	0.6	1

#	ARTICLE	IF	CITATIONS
307	Ground glass nodules with 5 yearsâ€™ stability can grow after 10-year follow-up: do genetic features determine the fate?. Translational Lung Cancer Research, 2019, 8, S425-S427.	2.8	1
308	New TNM Classification for Non-small Cell Lung Cancer by Evaluating T Factor Based on Tumor Size and Visceral Pleural Invasion. Japanese Journal of Lung Cancer, 2007, 47, 1-8.	0.1	1
309	Comparisons of the New TNM Staging System for Lung Cancer (UICC-7) and Revisions of the General Rules for the Clinical and Pathological Classification of Lung Cancer of the Japan Lung Cancer Society. Japanese Journal of Lung Cancer, 2012, 52, 80-84.	0.1	1
310	Adjuvant Chemotherapy in Patients with Completely Resected Lung Cancer: Investigation of the Current Situation After Publication of the Second Edition of Clinical Practice Guidelines for Lung Cancer. Japanese Journal of Lung Cancer, 2010, 50, 280-286.	0.1	1
311	Lung Adenocarcinoma Coexistent with Pulmonary Non-tuberculous Mycobacteriosis. Japanese Journal of Lung Cancer, 2012, 52, 238-241.	0.1	1
312	The History and Current State of EGFR-TKIs. Japanese Journal of Lung Cancer, 2017, 57, 69-74.	0.1	1
313	In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial. Lung Cancer, 2021, 162, 79-85.	2.0	1
314	Presence of a Ground-glass Opacity Component is the True Prognostic Determinant in Clinical Stage I Non-Small Cell Lung Cancer. JTO Clinical and Research Reports, 2022, 3, 100321.	1.1	1
315	Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405). International Journal of Clinical Oncology, 2022, 27, 1404-1412.	2.2	1
316	The close relationship between growth factors and the nucleolar organizer regions in adenocarcinoma of the lung. European Journal of Surgical Oncology, 1995, 21, 398-402.	1.0	0
317	Molecular Biology of Lung Cancer. Japanese Journal of Lung Cancer, 2010, 50, 329-341.	0.1	0
318	The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example. Annals of Pharmacotherapy, 2011, 45, 263-275.	1.9	0
319	Combined bevacizumab and erlotinib treatment in patients with lung cancer with the T790M resistance mutation. Lancet Respiratory Medicine, 2017, 5, 369-370.	10.7	0
320	Intra-tumor and inter-tumor heterogeneity in MET exon 14 skipping mutations and co-mutations in pulmonary pleomorphic carcinomas. Clinical Lung Cancer, 2021, , .	2.6	0
321	Mass Screening and Molecular Diagnosis for Lung Cancer. Japanese Journal of Lung Cancer, 2005, 45, 157-165.	0.1	0
322	Mutations in the Epidermal Growth Factor Receptor Gene And Sensitivity to Tyrosine Kinase Inhibitors. Japanese Journal of Lung Cancer, 2006, 46, 237-240.	0.1	0
323	Relationship Between Prognosis and Nodal Micrometastasis in Patients With Non-Small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2006, 46, 23-26.	0.1	0
324	Factors Affecting Postoperative Recurrence in Patients with Pathological Stage IB Non-small-cell Lung Cancer. Japanese Journal of Lung Cancer, 2007, 47, 327-332.	0.1	0

#	ARTICLE	IF	CITATIONS
325	The Significance of Changes in Serum CEA Level as a Surrogate Marker for Evaluating Tumor Response to Chemotherapy in Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2008, 48, 26-32.	0.1	0
326	EGFR Mutation, But Not Sex and Smoking, Is Independently Associated with Favorable Prognosis of Gefitinib-treated Patients with Lung Adenocarcinoma. Japanese Journal of Lung Cancer, 2009, 49, 409-415.	0.1	0
327	EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence. Journal of Cancer Research Updates, 0, , .	0.3	0
328	Abstract IA5: Genetic and genomic difference in lung cancer based on ethnicity. Clinical Cancer Research, 2012, 18, IA5-IA5.	7.0	0
329	Oncogenic driver mutations. , 2012, , 45-58.		0
330	Risk Assessment of Perioperative Mortality After Pulmonary Resection for Primary Lung Cancer: the 30-day or 90-day Mortality. Japanese Journal of Lung Cancer, 2013, 53, 93-98.	0.1	0
331	Mediastinal tumors associated with von Recklinghausen's disease.. The Journal of the Japanese Association for Chest Surgery, 1992, 6, 780-785.	0.0	0
332	Cavernous lymphangioma extending to the posterior mediastinum and the retroperitoneum; a case report.. The Journal of the Japanese Association for Chest Surgery, 1992, 6, 706-711.	0.0	0
333	Combined Carboplatin and Cisplatin Therapy in Patients with Advanced Non-Small Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 31-35.	1.3	0
334	Lung Cancer and <i>KRAS</i>-Its Molecular Biology/Genetics and Therapeutic Strategy-. Japanese Journal of Lung Cancer, 2022, 62, 188-199.	0.1	0